Chronic cough affects about 10% of people globally and can persist for many years, often requiring a multidisciplinary approach for diagnosis and treatment. Recent research suggests that chronic cough should be considered a distinct disease, with neurogenic mechanisms playing a significant role in some cases.| ENTtoday
Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
